期刊文献+

布地奈德福加莫特罗粉吸入剂治疗稳定期COPD的临床效果评价 被引量:3

Evaluation on the Clinical Effect of Using Budesonide and Formoterol Inhalant to Treat Patients with Stable COPD
下载PDF
导出
摘要 目的评价布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺病(COPD)患者的临床效果。方法依据纳入排除标准选取80例稳定期COPD患者,并随机分为两组,其中对照组采用噻托溴铵治疗,研究组在此基础上加用布地奈德和福莫特罗粉;比较两组患者的血气分析、肺功能指标以及临床疗效。结果研究组患者治疗后血气分析、肺功能指标均较对照组有明显改善;差异均有统计学意义(P﹤0.05);研究组治疗后的总有效率为90.00%,高于对照组(62.50%),差异有统计学意义(P﹤0.05)。结论布地奈德加福莫特罗粉吸入剂治疗治疗稳定期COPD患者的临床效果较佳,可有效改善病人的肺功能,避免症状加重,值得临床上推广使用。 OBJECTIVE To evaluate budesonide and formoterol inhalant for the treatment of stable chronic obstructive pulmonary dis-ease(COPD) patients with clinical effect. METHODS According to the inclusion and exclusion criteria,80 patients with stable COPD patients were selected and randomly divided into two groups, the control group was treated with tiotropium bromide in the treatment of, study group based on the use of budesonide/formoterol fumarate powder; compared two groups of patients with blood gas analysis,pulmonary function and clinical curative effect. RESULTS the blood gas analysis and pulmonary function index of the study group were significantly improved compared with the control group(P<0.05); the total effective rate of the study group was 90%, higher than the control group(62.50%), the difference was statistically significant(P<0.05). CONCLUSION Budesonide and formoterol fumarate powder for inhalation therapy in the treatment of COPD patients in the stable phase had clinical effect better, effectively improve the patient's pulmonary function and avoid symptoms,which was worthy of clinical use.
作者 李斌斌
机构地区 永嘉县人民医院
出处 《中国初级卫生保健》 2016年第1期82-83,共2页 Chinese Primary Health Care
关键词 慢性阻塞性肺病 布地奈德 福莫特罗 雾化吸入治疗 临床效果 linical effect chronic obstructive pulmonary disease budesonide formoterol
  • 相关文献

参考文献9

二级参考文献74

共引文献8443

同被引文献34

  • 1Guirguis-Blake JM,Senger CA,Webber EM,et al.Screening for Chronic Obstructive Pulmonary Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA,2016,315( 13): 1378-1393.
  • 2Panahi Y, Ghanei M,Behzadi M,et al.Investigation of the efficacy of generic and brand-name tiotropittm bromide in the management of chronic obstructive pulmonary disease:A randomized comparative trial[J].Saudi Pharm J,2016,24(2): 147-152.
  • 3Ulrik CS.Once-daily glycopyrronium bromide (Seebri Breezhaler(?)) for the treatment of chronic obstructive pulmonary disease (COPD)[J].Expert Opin Pharmaeoth er,2015,16( 17):2653 -2659.
  • 4Alvarado-Gonzalez A,Arce I.Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma[J].J Clin Med Res,2015,7(11):831-839.
  • 5Costa-Scharplatz M,St?llberg B,Goyal P, et al.Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden[J].Appl Health Econ Health Policy,2015,13 (6):637-645.
  • 6Luo Z,Liu CT, Wu CG,et al.Efficacy and Safety of Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease-a Multi-center Randomized Clinical Trial[J].Sichuan Da Xue Xue Bao Yi Xue Ban,2015,46(3):485-487.
  • 7Ferguson GT, Fle?ar M,Korn S,et al.Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis[J].Adv Ther,2015,32(6):523-536.
  • 8梁远贵.布地奈德/福莫特罗干粉吸入剂治疗稳定期中度慢性阻塞性肺疾病疗效观察[J].现代医药卫生,2013,29(10):1456-1457. 被引量:5
  • 9刘勇,解玉东.布地奈德/福莫特罗干粉吸入剂联合噻托溴铵治疗中重度稳定期COPD疗效评价[J].中国实用医药,2013,8(16):165-166. 被引量:19
  • 10朱勤瑞,周政敏.沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病合并呼吸衰竭患者超敏C反应蛋白和脑钠肽的影响[J].医学综述,2014,20(6):1106-1108. 被引量:13

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部